alogliptin
AZ and Takeda diabetes drugs get FDA safety update
April 15, 2015Manufacturing and Production, Sales and Marketing AstraZeneca, FDA, Nesina, Onglyza, Takeda, alogliptin, cardiovascular, diabetes, saxagliptin
An FDA advisory committee has said that the labels of two type 2 diabetes drugs should be changed to warn …
AstraZeneca diabetes drug could ‘significantly’ increase mortality
April 13, 2015Research and Development, Sales and Marketing AstraZeneca, FDA, Nesina, Onglyza, Takeda, alogliptin, cardiovascular, saxagliptin
AstraZeneca’s diabetes drug Onglyza may lead to a ‘significant increase’ in risk of death according to a new analysis from …
Latest content
EnteroBiotix appoints former GSK Chief Medical Officer to board
November 3, 2026
AI: an early warning system for patient safety
November 3, 2026
